Bausch Health Companies Inc
NYSE:BHC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.22
10.61
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BHC stock under the Base Case scenario is 73.26 USD. Compared to the current market price of 8.32 USD, Bausch Health Companies Inc is Undervalued by 89%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bausch Health Companies Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BHC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bausch Health Companies Inc
Balance Sheet Decomposition
Bausch Health Companies Inc
Current Assets | 5.2B |
Cash & Short-Term Investments | 595m |
Receivables | 2.1B |
Other Current Assets | 2.5B |
Non-Current Assets | 21.3B |
PP&E | 1.7B |
Intangibles | 17B |
Other Non-Current Assets | 2.5B |
Current Liabilities | 4.4B |
Accounts Payable | 579m |
Accrued Liabilities | 3.3B |
Other Current Liabilities | 530m |
Non-Current Liabilities | 23.3B |
Long-Term Debt | 21.2B |
Other Non-Current Liabilities | 2.1B |
Earnings Waterfall
Bausch Health Companies Inc
Revenue
|
9.2B
USD
|
Cost of Revenue
|
-2.7B
USD
|
Gross Profit
|
6.5B
USD
|
Operating Expenses
|
-4.8B
USD
|
Operating Income
|
1.7B
USD
|
Other Expenses
|
-2.2B
USD
|
Net Income
|
-471m
USD
|
Free Cash Flow Analysis
Bausch Health Companies Inc
USD | |
Free Cash Flow | USD |
Bausch Health has demonstrated consistent growth, marking its fifth consecutive quarter of year-over-year revenue and adjusted EBITDA increases. In Q2 2024, revenue grew by 5% to $1.19 billion, driven by strong performances in key segments like XIFAXAN, which saw 10% growth, and Solta, which grew by 19%. The company maintained its 2024 guidance with expected revenue between $4.7 billion and $4.85 billion and adjusted EBITDA ranging from $2.36 billion to $2.46 billion. Debt reduction efforts were highlighted by the repayment of $360 million in Q2, underscoring a commitment to financial stability.
What is Earnings Call?
BHC Profitability Score
Profitability Due Diligence
Bausch Health Companies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Bausch Health Companies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
BHC Solvency Score
Solvency Due Diligence
Bausch Health Companies Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Bausch Health Companies Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BHC Price Targets Summary
Bausch Health Companies Inc
According to Wall Street analysts, the average 1-year price target for BHC is 6.8 USD with a low forecast of 6.36 USD and a high forecast of 7.39 USD.
Dividends
Current shareholder yield for BHC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BHC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 19,600 full-time employees. The firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.
Contact
IPO
Employees
Officers
The intrinsic value of one BHC stock under the Base Case scenario is 73.26 USD.
Compared to the current market price of 8.32 USD, Bausch Health Companies Inc is Undervalued by 89%.